Alpha Cognition announces marketing services for Canadian business journals.

Not intended for distribution in the United States
or through the newswire service

VANCOUVER, British Columbia, November 17, 2022 (GLOBE NEWSWIRE) — Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG) (OTCQB: ACOGF) is a biopharmaceutical company It has the potential to transform the lives of people with degenerative diseases.

The offering will be made on a best effort agency basis pursuant to the terms of the agency agreement entered into between the Company and Raymond James Ltd. as sole bookrunner and lead agent on behalf of a syndicate of agents including IA Private. is carried out in Wealth Inc., Echelon Wealth Partners and Leede Jones Gable Inc. (collectively, “Agents”).

The pricing, terms and size of the offering will be determined subject to market conditions at the time of the final agency agreement between us and our agents. The Company also grants Agents the option to sell up to 15% of the Units sold under the Offering at the Issue Price (“Over-allotment Option”). An over-allotment option may, at any time within thirty (30) days from the closing date of the offering, upon written notice to the Company, purchase common stock, warrants, or units as determined by the Agent, in whole or in part. can exercise.

The offering is made pursuant to the Company’s Canadian Basic Prospectus dated February 24, 2022 (the “Basic Prospectus”). A prospectus supplement relating to the offering (“Prospectus Supplement”) will be filed in each province of Canada except Quebec. A copy of the prospectus supplement and accompanying base shelf prospectus is available through SEDAR’s company profile at www.sedar.com.

The Company intends to use the net proceeds of the offering for clinical development and marketing of its Alpha-1062 and Alpha-0602 formulations, as well as for working capital and general corporate purposes.

The offering is expected to close on or around November 25, 2022, subject to customary closing conditions.

Closing of the offering is subject to certain conditions, including without limitation receipt of all necessary approvals, including TSX Venture Exchange approvals.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and no sale of securities shall be made in the United States or any other jurisdiction where such offer, solicitation or sale would be unlawful. increase. These securities have not been registered under the United States Securities Act of 1933, as amended, and will be offered or sold in the United States unless registered or subject to an applicable exemption from the requirements for registration under that Act. I can not do it.

About Alpha Cognition

Alpha Cognition Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases with limited treatment options, such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) .

ALPHA-1062 is a patented novel chemical being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease with minimal expected gastrointestinal side effects. The active metabolite of ALPHA-1062 is distinct from donepezil and rivastigmine in that it binds to neuronal nicotinic receptors, particularly the α-7 subtype, which is known to have positive effects on cognition. ALPHA-1062 is also being developed as an intranasal formulation for traumatic brain injury in combination with memantine to treat moderate to severe Alzheimer’s disease.

ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and peripheral tissues, promotes cell survival, regulates certain inflammatory processes, and regulates lysosomal function and microglial response to disease. play an important role in An intended use for the treatment of neurodegenerative diseases has been patented by the Company, and ALPHA-0602 has been granted orphan drug designation by the FDA for the treatment of ALS. ALPHA-0702 and ALPHA-0802 are granulin epithelin motifs (GEMs) derived from full-length progranulin and have therapeutic potential across multiple neurodegenerative diseases. GEMs have been shown to be important in cell proliferation, survival, repair, and regulation of inflammation. ALPHA-0702 and ALPHA-0802 are designed to offer this because of their low toxicity and potentially high therapeutic efficacy.

For more information:

Bristol Investor Relations
Stephen Eftikiu
905 326 1888 ext. 6
[email protected]
https://www.alphacognition.com/

Alpha Cognition Co., Ltd.
Michael McFadden
858 344 4375
[email protected]
https://www.alphacognition.com/

Neither TSX Venture Exchange (“TSX-V”), OTC Markets Group, or TSX-V’s regulated service provider (as such terms are defined in TSX-V’s Policy) is responsible for the adequacy or accuracy of this release. We do not owe.

Forward-Looking Statements

Certain statements in this release may contain forward-looking information.All statements, other than historical facts, that address future activities, events or developments that we believe, expect or anticipate will occur or may occur (the offering generally, its terms and , the use of its proceeds, the exercise of the over-allotment option and the satisfaction of the closing conditions of the offering, including the timely receipt of required approvals, are forward-looking statements. could, will, should, continue, expect, predict, estimate, believe, intend, plan can be identified by using the words “will” or “project”, or negative forms of these words, or other variations of these words, or equivalent terms. Forward-looking statements involve a number of risks. and uncertainties, many of which are beyond our control or ability to predict, that could cause our actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, the inability to raise sufficient funds to carry out our business plans. the success of our research and development strategy, the applicability of the discoveries made therein, the success and timeliness of our research and development strategy, including but not limited to: competition; and uncertainties associated with the regulatory process, the timing of clinical trials, the timing and results of regulatory or intellectual property decisions, and other matters disclosed in the company’s public records filed with relevant securities regulators. Risks: Although we have attempted to identify important factors that could cause actual results or events to differ materially from those set forth in the forward-looking statements, results or events may not be projected, There may be other factors that may cause the results to differ from those estimated or intended.You should not place undue reliance on the forward-looking statements contained in this news release. Statements are made as of the date of this news release and the Company reserves the right to make revisions to them to reflect new information, subsequent events or otherwise, unless required by the applicable security. We undertake no obligation to publicly update any forward-looking statements such as legislation.

CBJ Newsmaker